- Home
- TSI vs CDXS Comparison
TSI vs CDXS Comparison
Compare TSI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- CDXS
- Stock Information
- Founded
- TSI 1987
- CDXS 2002
- Country
- TSI United States
- CDXS United States
- Employees
- TSI N/A
- CDXS N/A
- Industry
- TSI Investment Managers
- CDXS Major Chemicals
- Sector
- TSI Finance
- CDXS Industrials
- Exchange
- TSI Nasdaq
- CDXS Nasdaq
- Market Cap
- TSI 235.1M
- CDXS 216.6M
- IPO Year
- TSI N/A
- CDXS 2010
- Fundamental
- Price
- TSI $4.93
- CDXS $2.15
- Analyst Decision
- TSI
- CDXS Buy
- Analyst Count
- TSI 0
- CDXS 2
- Target Price
- TSI N/A
- CDXS $11.00
- AVG Volume (30 Days)
- TSI 106.8K
- CDXS 602.1K
- Earning Date
- TSI 01-01-0001
- CDXS 11-06-2025
- Dividend Yield
- TSI 7.46%
- CDXS N/A
- EPS Growth
- TSI N/A
- CDXS N/A
- EPS
- TSI N/A
- CDXS N/A
- Revenue
- TSI N/A
- CDXS $57,164,000.00
- Revenue This Year
- TSI N/A
- CDXS $12.88
- Revenue Next Year
- TSI N/A
- CDXS $21.64
- P/E Ratio
- TSI N/A
- CDXS N/A
- Revenue Growth
- TSI N/A
- CDXS N/A
- 52 Week Low
- TSI $4.48
- CDXS $1.90
- 52 Week High
- TSI $4.87
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- TSI 50.02
- CDXS 32.47
- Support Level
- TSI $4.88
- CDXS $2.52
- Resistance Level
- TSI $4.96
- CDXS $2.80
- Average True Range (ATR)
- TSI 0.04
- CDXS 0.15
- MACD
- TSI 0.00
- CDXS -0.05
- Stochastic Oscillator
- TSI 62.50
- CDXS 3.73
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.